News Summary
NeutralDanaher delivered a solid Q2 2026 earnings beat with raised full-year EPS guidance to $8.45–$8.60, driven by accelerating non-respiratory growth (4.5%) and successful Masimo integration. However, bioprocessing revenue delays to 2027 and reduced growth expectations triggered an 11% post-earnings stock decline, and the stock remains down 20% year-to-date despite analyst confidence in the structural recovery narrative.
Red flags
- •Bioprocessing revenue delayed to 2027 due to customer timing, raising uncertainty about recovery pace
- •Stock fell 11% immediately post-earnings despite beating consensus, signaling investor concern about forward visibility
- •Stock down 20% year-to-date despite raised guidance, indicating persistent market skepticism
- •Guidance raised only modestly despite Q2 beat, suggesting management conservatism on near-term bioprocessing demand
Funds Buying (5)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Glenview Capital | Larry Robbins | 1.1M | +990K | $218M | 4.4% | +633% | Existing |
| Third Point | Dan Loeb | 540K | +15K | $103M | 2.2% | +3% | Existing |
| Tiger Global | Chase Coleman | 456K | +456K | $87M | 0.4% | — | NEW |
| Duquesne Family Office | Stanley Druckenmiller | 50K | +50K | $10M | 0.2% | — | NEW |
| Point72 | Steve Cohen | 11K | +11K | $2M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where DHR ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #7 of this fund's book
- 4THERMO FISHER SCIENTIFIC INC$314M
- 5AMAZON COM INC$303M
- 6AGILENT TECHNOLOGIES INC$262M
- 7DANAHER CORP DEL$218M
- 8META PLATFORMS INC$201M
- 9ADVANCED MICRO DEVICES INC$173M
- 10TEVA PHARMACEUTICAL INDS LTD$172M
position #19 of this fund's book
- 16API GROUP CORP$121M
- 17MASTEC INC$121M
- 18TRANSDIGM GROUP INC$105M
- 19DANAHER CORP DEL$103M
- 20UNION PAC CORP$95M
- 21TTM TECHNOLOGIES INC$94M
- 22PERFORMANCE FOOD GROUP CO$75M
position #32 of this fund's book
- 29CHIME FINL INC$108M
- 30EQUIPMENTSHARE COM INC$90M
- 31SHERWIN WILLIAMS CO$89M
- 32DANAHER CORP DEL$87M
- 33SERVICENOW INC$87M
- 34SPACE EXPLORATION TECHN CORP$64M
- 35WEBULL CORP$44M
Values are quarter-end position sizes. Shown only for funds where DHR ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Vanguard Capital Management | SC 13G | 47.4M | 6.7% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.